Navigation Links
Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
Date:12/2/2008

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade.

The new Pharmacor report entitled Psoriasis finds that the overall psoriasis drug market will grow from $2.3 billion in 2007 to $5 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Following their launches by 2012, the uptake of Stelara and Abbott's ABT-874 will be particularly robust, owing to their novel mechanism of action, durable efficacy and infrequent administration. In 2017, Stelara and ABT-874 will capture 21 percent of sales in the moderate to severe psoriasis market.

Between 2007 and 2017, up to nine biologics will be available to treat psoriasis and the number of biologic-treated patients in the psoriasis market will grow significantly, according to the report. Among patients treated with a systemic drug therapy, the percentage of biologic-treated patients will double, growing from 23 percent in 2007 to 46 percent in 2017.

"With the recent launch of Humira and the highly anticipated launch of Stelara as early as December 2008, we expect a reshuffling to occur in the current order of first-line biologic agents for the treatment of psoriasis," said Joanna Kim, analyst at Decision Resources. "We forecast that Humira and Stelara will join Enbrel as first-line biologics for moderate to severe psoriasis by 2012."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                   Decision Resources, Inc.
    Christopher Comfort                  Elizabeth Marshall
    781-296-2597                         781-296-2563
    ccomfort@dresources.com              emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
2. CVS Caremark Applauds FTCs Leadership on Follow-on Biologics
3. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
4. RTI Biologics Sees Expanded Surgeon User Base of Fresh OC Allografts
5. Biologics Dont Raise Cancer Risk in Rheumatoid Arthritis Patients
6. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
7. Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohns Disease
8. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
9. Children in Blended Families Still Close to Biological Mothers
10. Biological marker for Alzheimers holds promise for earlier diagnosis and treatment
11. Migraine mutations reveal clues to biological basis of disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: